A TEST TO ASSESS PROSTATE CANCER AGGRESSIVENESS

This test measures the expression levels of the genes involved in cell cycle progression. At the time of diagnosis, Prolaris can help to identify patients with less aggressive cancer who may be candidates for active surveillance. In addition, Prolaris can identify patients who appear clinically low-risk but have a more aggressive disease that requires more aggressive treatment. Visit Prolaris.com to learn more about this unique test.

Get a Free Patient Brochure

For better decision-making in prostate cancer treatment plans

This free information pack will help you and your physician decide if Prolaris is right for you.Receiving a Prolaris Score can help you move forward in your treatment plan with confidence.

Learn More

Medicare has announced expanded coverage of Prolaris.

Now patients with Medicare at NCCN favorable intermediate-risk have Medicare coverage, in addition to very low- and low-risk.

Recommended Links